Apellis Pharmaceuticals (APLS) reported a Q4 net loss Friday of $0.29 per diluted share, narrower than its loss of $0.73 per share a year earlier.
Analysts polled by FactSet expected a loss of $0.37.
Revenue for the quarter ended Dec. 31 was $212.5 million, up from $146.4 million a year earlier.
Analysts surveyed by FactSet expected $198.8 million.
The company said it had cash and cash equivalents of $411.3 million as of Dec. 31.
Shares of Apellis were up more than 9% in recent premarket activity Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。